This eNews focuses on exciting developments at Indoor Biotechnologies UK facilities in Cardiff.
The UK team has recently commissioned a new Environmental Testing Suite (ETS) which has been designed to AHAM AC-1 standards. This facility has independent air filtration and temperature controls and provides enhanced testing of cleaning products, air filtration devices and personal care products for validating product claims.
Coupled with the ETS, Indoor Biotechnologies UK has also developed product efficacy testing to measure the virucidal effects of disinfectants and cleaning agents in suspension or surface testing. Product efficacy testing for SARS-Cov-2 (using vaccinia or representative human coronaviruses) can be established to EN 14476 standards.
Completing this trifecta, we are delighted to announce that the UK team has developed a simple test for T cell immunity to SARS-Cov-2 virus. Preliminary studies funded by Innovate UK showed that 100% of donors with positive PCR tests to SARS-CoV-2 gave positive results in the T cell test, which is very encouraging. Further validation of the T cell test is in progress.
Finally, our UK company has seen tremendous growth and development in recent years. The architect of this expansion has been Dr. James Hindley (Executive Director) whose leadership, entrepreneurship, initiative and enthusiasm has greatly increased the visibility of Indoor Biotechnologies since he joined the company in 2012. Sadly, James will be leaving Indoor Biotechnologies in December to pursue other opportunities. We appreciate James’ service to Indoor Biotechnologies, and to the allergy community in general, and wish him every success in his future endeavours.
In the interim, Dr. Hayley Mills will be assuming James responsibilities. Please contact Hayley about business opportunities with Indoor Biotechnologies in the UK and the EU.
Enjoy the ETS and viral testing videos!
PS Have you made the transition to ELISA 2.0? Indoor Biotechnologies will discontinue ELISA-10 kits on December 31st – see details below.
Environmental Testing – SUITE!
Indoor Biotechnologies has expanded facilities and commissioned a new and improved Environmental Testing Suite (ETS) in Cardiff, Wales.
The ETS contains a Dry room and a Wet room to mimic a small bedroom/living area and bathroom. Each room has independent HEPA filtered air and temperature control and the Dry room has been designed to AHAM AC-1 standards.
The suite is primarily used to test the safety and efficacy of home and personal care products including air purification devices, cleaning products, vacuum cleaners, carpets and textiles. The facility supports all stages of product development, from R&D, to formulation testing and validation of end-product claims. Comprehensive allergen testing is provided onsite.
To reserve the ETS to support your product development, contact Dr. Hayley Mills.
Take a tour of Indoor Biotechnologies’ new Environmental Testing Suite.
Indoor Biotechnologies now offers a broad range of viral testing, including virucidal activity and assessments of virus viability on surfaces. Suspension and surface tests are in accordance with EN 14476, EN 16777, ASTM E10532 and ASTM E1053 standards. Custom testing methods can be designed on a contract research basis in collaboration with our scientists with expertise in viral immunology.
Indoor Biotechnologies laboratories in the UK and India have tissue culture facilities that operate under Biosafety Level 2 and are ISO 17025 compliant.
Watch this video to learn more about Indoor Biotechnologies’ virucidal efficacy testing capabilities.
A note on SARS-CoV-2
In accordance with EN 14476 standards, products shown to be effective against Vaccinia virus can be deemed effective against all enveloped viruses, including coronaviruses.
Human Coronavirus 229E and OC43 can also be used as surrogates for SARS-CoV-2.
Indoor Biotechnologies provide testing with these viruses to support virucidal efficacy claims against coronaviruses, including SARS-CoV-2.
Please contact Dr. Maria Oliver for further information.
Novel COVID-19 T cell Test
T cells play a critical role in controlling and eradicating viral infections. Funded by an Innovate UK grant, Indoor Biotechnologies has successfully developed a simple test for T cell immunity to SARS-CoV-2, the virus which causes Covid-19.
From a single tube of whole blood, the test can identify memory T cells that respond to the virus within 24 hours. Preliminary data, obtained through a collaboration with Dr. Martin Scurr at Cardiff University, showed that all (100%) PCR +ve donors (n=15) and 85% of antibody +ve donors (n=20) gave positive Tcell responses, as compared with 25% of antibody -ve donors (n=61).
Indoor Biotechnologies T cell test is easy to use and should enable widespread testing of Covid-19 T cell immunity. Applications include analysing T cell responses in symptomatic and asymptomatic COVID-19 patients, monitoring vaccine development and evaluating the longevity of T cell immune responses.
Indoor Biotechnologies Ltd is completing validation of the test and will obtain CE marking prior to commercialization in the UK and EU.
To find out more or discuss opportunities for collaborations or partnerships, please contact Dr. Maria Oliver.
ELISA 2.0 – Making the Transition
Indoor Biotechnologies has decided it’s time to say goodbye to ELISA-10 kits and will discontinue manufacture of these kits by December 31, 2020.
We invite you to join us in the transition to ELISA 2.0, our significantly improved replacement assay kit. ELISA 2.0 makes allergen measurements easier, more sensitive, less time consuming, and more readily standardized. See attached letter and White Paper.
Indoor Biotechnologies will continue to supply a comprehensive range of individual monoclonal antibodies for other experimental purposes such as immunoblotting and immunohistochemistry.